NuView Life Sciences is a privately held company whose mission is the discovery, development and commercialization of a new generation of diagnostic imaging probes and disease specific biomarkers.

NUVIEW Life Sciences, in collaboration with prestigious research universities and top medical centers, is a leader in molecular imaging technology with an active pipeline of promising PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Technology) compounds currently involved in pre FDA trials. Both clinical modalities are rapidly advancing, leading the way to to the future of diagnostic imaging and novel therapeutic choices.

NUVIEWS ‘s products of innovative technology have the potential for the earliest detection of disease, allowing physicians to better define and personalize treatment options for patients with cardiovascular and cancer. This is possible because our products are developed and designed to detect first stage microscopic change before symptoms or structural defects occur, subsequently defining earlier and better treatment options that will improve patient outcomes and reduce overall healthcare cost.

At NuView, we are a company with a “new view” on how to revolutionize healthcare, creating an enhanced quality of health and life.